Mild or moderate atopic dermatitis

Active Ingredient: Pimecrolimus

Indication for Pimecrolimus

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Treatment of patients aged 2 years and over with mild or moderate atopic dermatitis where treatment with topical corticosteroids is either inadvisable or not possible. This may include:

  • Intolerance to topical corticosteroids.
  • Lack of effect of topical corticosteroids.
  • Use on the face and neck where prolonged intermittent treatment with topical corticosteroids may be inappropriate.

For this indication, competent medicine agencies globally authorize below treatments:

2 spreads in 2 divided doses daily

Route of admnistration

Cutaneous

Defined daily dose

2 - 2 {spreads}

Dosage regimen

From 1 To 1 {spreads} 2 time(s) per day every day

Detailed description

Adults

Apply a thin layer of pimecrolimus to the affected skin twice daily and rub in gently and completely. Each affected region of the skin should be treated with pimecrolimus until clearance occurs and then treatment should be discontinued.

Pimecrolimus may be used on all skin areas, including the head and face, neck and intertriginous areas, except on mucous membranes. Pimecrolimus should not be applied under occlusion.

In the long-term management of atopic dermatitis (eczema), pimecrolimus treatment should begin at first appearance of signs and symptoms of atopic dermatitis to prevent flares of the disease. Pimecrolimus should be used twice daily. Emollients can be applied immediately after using pimecrolimus.

Paediatric patients

The use of pimecrolimus in patients under 2 years of age is not recommended until further data become available.

For children (2-11 years) and adolescents (12-17 years) the posology and method of administration are the same as for adults.

Active ingredient

Pimecrolimus

Pimecrolimus is a lipophilic anti-inflammatory ascomycin macrolactam derivative and a cell selective inhibitor of the production and release of pro-inflammatory cytokines.

Read more about Pimecrolimus

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.